Gastrointestinal and Health-related Quality of Life Outcomes in Patients With Simultaneous Pancreas-Kidney Transplants
Status:
Completed
Trial end date:
2008-01-01
Target enrollment:
Participant gender:
Summary
Treatment with the immunosuppressive drug mycophenolate mofetil (MMF) may result in
gastrointestinal (GI) complications in some patients. This study will assess if a switch from
MMF to enteric-coated mycophenolate sodium (EC-MPS) results in improved GI and/or
health-related quality of life outcomes and determine the proportion of pancreas-kidney
transplant recipients who experience any GI complaints under MMF-based immunosuppressive
treatment.